Please login to the form below
RoActemra
This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.
CAR-Ts Kymriah and Yescarta step closer to approval in Europe
The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.
Latest news
-
Roche's Actemra/RoActemra receives new European approval
Roche's Actemra/RoActemra receives new European approval. EU regulators also pass the Swiss pharma firm’s Gazyvaro. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition
-
Ocrevus off to a flying start as Roche raises 2017 forecasts
Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
-
Sanofi/Regeneron bag first approval for Actemra rival sarilumab
Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
-
Manufacturing issues scupper Sanofi's sarilumab launch plans
Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
-
Roche snags pair of FDA breakthrough designations
Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen
More from news
Approximately 5 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Opening up innovation
If approved it will compete with the likes of Roche's RoActemra (tocilizumab). “
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Infographic: RA Perceptions
Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
Infographic: RA Perceptions
Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
-
Brand leaders in RA will lose market share, predict rheumatologists
market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
-
Account Manager
-
Negotiable
- Account Director or Senior Account Director
-
Salary TBC
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Sudler London - Senior Medical Writer
-
Competitive
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Anatomy Health
We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
